Imel Biotherapeutics
Imel Biotherapeutics: Innovating cell-based therapies for mitochondrial disorders since 2019.
Founded
2019Imel Biotherapeutics: Innovating cell-based therapies for mitochondrial disorders since 2019.
Imel Biotherapeutics, founded in 2019 and based in Waltham, Massachusetts, focuses on developing innovative cell-based therapies to treat mitochondrial disorders. The company leverages its proprietary mitochondrial replacement cells technology to address both genetic and age-related mitochondrial dysfunctions. Imel Biotherapeutics aims to enhance the functionality of T cells through mitochondrial replacement, helping physicians treat a wide range of patients with compromised immune systems.
Notable figures associated with Imel Biotherapeutics include leading scientists and industry experts in mitochondrial research and cell therapy. The company has attracted significant interest from investors in the biotech sector due to its groundbreaking approach. Key achievements include demonstrating over 90% replacement of dysfunctional mitochondria in reprogrammed T cells, which regain functionality and overcome exhaustion. Imel Biotherapeutics is poised to make a substantial impact on the treatment of mitochondrial disorders and immune system rejuvenation.
Companies similar to Imel Biotherapeutics include Cellvie, HebeCell, IM Therapeutics and Mitosense.
Imel Biotherapeutics was founded in 2019.
Imel Biotherapeutics' headquarters is located in Waltham, MA, US.
Imel Biotherapeutics' most recent funding round was for $15M (USD) in November 2021.
As of Nov 15, 2021, Imel Biotherapeutics has disclosed funding of $15M (USD). Undisclosed round amounts are excluded.
Imel Biotherapeutics has 6 employees as of Feb 5, 2024.
Mitosense
mitosenseinc.com
